Travere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 2,174 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 2,174 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $46.65, for a total value of $101,417.10. Following the completion of the sale, the insider owned 107,287 shares in the company, valued at approximately $5,004,938.55. This represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Stock Performance

TVTX opened at $44.70 on Thursday. The stock has a market cap of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The stock’s 50 day simple moving average is $32.59 and its 200 day simple moving average is $32.83. Travere Therapeutics, Inc. has a 1-year low of $13.88 and a 1-year high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company’s revenue was up 55.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.47) EPS. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. State of Wyoming purchased a new position in shares of Travere Therapeutics during the 4th quarter worth $37,000. Torren Management LLC purchased a new position in shares of Travere Therapeutics during the 4th quarter worth $38,000. Comerica Bank lifted its stake in shares of Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after purchasing an additional 492 shares during the period. Fifth Third Bancorp purchased a new position in shares of Travere Therapeutics during the 1st quarter worth $35,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after purchasing an additional 487 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen cut Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Guggenheim increased their target price on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. Canaccord Genuity Group increased their target price on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Wedbush increased their target price on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, TD Cowen increased their target price on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: CEO Form 4

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.